Your browser doesn't support javascript.
loading
Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice.
Branca, Jane A; Low, Benjamin E; Saxl, Ruth L; Sargent, Jennifer K; Doty, Rosalinda A; Wiles, Michael V; Dumont, Beth L; Hasham, Muneer G.
Afiliação
  • Branca JA; The Jackson Laboratory, Bar Harbor, Maine, USA.
  • Low BE; The Jackson Laboratory, Bar Harbor, Maine, USA.
  • Saxl RL; The Jackson Laboratory, Bar Harbor, Maine, USA.
  • Sargent JK; The Jackson Laboratory, Bar Harbor, Maine, USA.
  • Doty RA; The Jackson Laboratory, Bar Harbor, Maine, USA.
  • Wiles MV; The Jackson Laboratory, Bar Harbor, Maine, USA.
  • Dumont BL; The Jackson Laboratory, Bar Harbor, Maine, USA.
  • Hasham MG; The Jackson Laboratory, Bar Harbor, Maine, USA.
Genes Cancer ; 11(1-2): 83-94, 2020.
Article em En | MEDLINE | ID: mdl-32577159
ABSTRACT
Known as the guardian of the genome, transformation-related protein 53 (TRP53) is a well -known tumor suppressor. Here, we describe a novel TRP53 deficient mouse model on a tumor prone background-SJL/J mice. The absence of TRP53 (TRP53 nullizygosity) leads to a shift in the tumor spectrum from a non-Hodgkin's-like disease to thymic lymphomas and testicular teratomas at a very rapid tumor onset averaging ~12 weeks of age. In haplotype studies, comparing tumor prone versus tumor resistant Trp53 null mouse strains, we found that other tumor suppressor, DNA repair and/or immune system genes modulate tumor incidence in TRP53 null strains, suggesting that even a strong tumor suppressor such as TRP53 is modulated by genetic background. Due to their rapid development of tumors, the SJL/J TRP53 null mice generated here can be used as an efficient chemotherapy or immunotherapy screening mouse model.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article